FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Factor Viii topics
Factor Viii
Nucleotide
Antibodies
Polynucleotide
Polypeptide
Sialic Acid
Circulatory
Recombinant
Ethylene Glycol
Coagulation
Hemophilia
Physiologic
Endogenous
Prophylaxis
Blood Coagulation

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Factor Viii patents



      
           
This page is updated frequently with new Factor Viii-related patents. Subscribe to the Factor Viii RSS feed to automatically get the update: related Factor RSS feeds.

Subscribe to updates on this page: Factor Viii RSS RSS

Date/App# patent app List of recent Factor Viii-related patents
03/13/14
20140072561
 Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life patent thumbnailFactor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life
The present invention relates to modified nucleic acid sequences coding for coagulation factor viii (fviii) and for von willebrand factor (vwf) as well as complexes thereof and their derivatives, recombinant expression vectors containing such nucleic acid sequences, host cells transformed with such recombinant expression vectors, recombinant polypeptides and derivatives coded for by said nucleic acid sequences which recombinant polypeptides and derivatives do have biological activities together with prolonged in vivo half-life and/or improved in vivo recovery compared to the unmodified wild-type protein. The invention also relates to corresponding fviii sequences that result in improved expression yield.
02/27/14
20140057848
 Factor viii variants having a decreased cellular uptake patent thumbnailFactor viii variants having a decreased cellular uptake
The present invention relates to modified coagulation factors. In particular, the present invention relates to modified factor viii molecules having decreased cellular uptake..
02/27/14
20140056861
 Recombinant factor viii having increased stability patent thumbnailRecombinant factor viii having increased stability
The present invention relates to a recombinant factor viii that includes one or more mutations that result in enhanced stability of both factor viii and factor viiia. Methods of making and using the recombinant factor viii, and pharmaceutical compositions containing the same are also disclosed.
02/20/14
20140051832
 Method for the production of recombinant human factor viii patent thumbnailMethod for the production of recombinant human factor viii
The object of the present invention is to provide methods for the production of recombinant human factor viii, employing specific endoproteases, thus assuring full proteolytic processing of said factor even during its biosynthesis, consequently avoiding additional purification steps. Other objects of the present invention are the recombinant human factor viii as obtained by said methods, pharmaceutical compositions, related uses and therapeutic methods..
02/20/14
20140051123
 Method of increasing the productivity of eucaryotic cells in the production of recombinant fviii patent thumbnailMethod of increasing the productivity of eucaryotic cells in the production of recombinant fviii
A method of increasing productivity, in particularly cell-specific productivity, of recombinant factor viii (rfviii) produced in a eukaryotic cell suspension during culturing of the eucaryotic cell suspension in a culturing medium containing not more than 500 μm cacl2, at least a non-ionic detergent and other nutrient components needed for the cells to grow and produce rfviii, the cell suspension is cultured under conditions inducing a shear stress mechanically to the eucaryotic cell suspension by adding a power density of at least 3 w/m3.. .
02/06/14
20140037632
 Multi-specific antigen-binding molecules and uses thereof patent thumbnailMulti-specific antigen-binding molecules and uses thereof
Various bispecific antibodies that specifically bind to both blood coagulation factor ix/activated blood coagulation factor ix and blood coagulation factor x and functionally substitute for the cofactor function of blood coagulation factor viii, that is, the function to promote activation of blood coagulation factor x by activated blood coagulation factor ix, were produced. From these antibodies, multispecific antigen-binding molecules having a high activity of functionally substituting for blood coagulation factor viii were successfully discovered..
01/23/14
20140024808
 Factor viii polymer conjugates patent thumbnailFactor viii polymer conjugates
The invention is a proteinaceous construct comprising a factor viii molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of factor viii, and methods of preparing same.. .
01/16/14
20140018297
 Compounds suitable for treatment of haemophilia patent thumbnailCompounds suitable for treatment of haemophilia
The present invention relates to von willebrand (vwf) compounds as well as compositions suitable for treatment of blood clotting diseases. The present invention also relates to pharmaceutical compositions, freeze-dried or liquid, comprising (i) a factor viii molecule and (ii) a vwf compound..
12/26/13
20130345403
 Aqueous factor viii solution patent thumbnailAqueous factor viii solution
The present invention relates to methods for stabilizing fviii in aqueous solutions comprising a relatively high concentration of fviii. The invention furthermore relates to such aqueous solutions as well as use thereof..
12/12/13
20130330345
 Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii patent thumbnailMulti-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
Various bispecific antibodies that specifically bind to both blood coagulation factor ix/activated blood coagulation factor ix and blood coagulation factor x and functionally substitute for the cofactor function of blood coagulation factor viii, that is, the function to promote activation of blood coagulation factor x by activated blood coagulation factor ix, were produced. From these antibodies, multispecific antigen-binding molecules having a high activity of functionally substituting for blood coagulation factor viii were successfully discovered..
11/07/13
20130296244
Variant of antihemophilic factor viii having increased specific activity
The present invention is in the field of hemophilia therapy. It relates to a new variant of antihemophilic factor viii having increased specific activity in comparison to known factor viii products..
11/07/13
20130296243
Modified recombinant factor viii and von willebrand factor and methods of use
The present invention provides novel methods of increasing the survival of a coagulation protein by inhibiting the interaction with a clearance receptor. The invention also provides methods of preparing compositions that inhibit coagulation protein clearance receptors.
10/24/13
20130281671
Systems for factor viii processing and methods thereof
The present invention provides methods of reducing nonprocessed factor viii or a chimeric polypeptide comprising factor viii comprising co-transfecting in a host cell a polynucleotide encoding factor viii with a polynucleotide encoding a protein convertase, where the endogenous processing enzymes of the host cell are insufficient to convert all of the factor viii to its processed isoform; expressing a proprotein convertase from a second polynucleotide in the host cell; and reducing the nonprocessed factor viii by processing with said proprotein convertase.. .
10/17/13
20130274445
Factor viii conjugates
This invention relates to factor viii muteins that are covalently bound, at a predefined site that is not an n-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain fviii procoagulant activity and have improved pharmacokinetic properties..
10/17/13
20130274194
Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
The present invention provides methods of administering factor viii; methods of administering chimeric and hybrid polypeptides comprising factor viii; chimeric and hybrid polypeptides comprising factor viii; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.. .
10/10/13
20130267468
Factor viii glycoforms
The invention concerns glycosylated proteins having human factor viii activity. In a preferred embodiment, the protein is glycosylated with oligosaccharides that include an alpha-(2,6)-linked sialic acid and a bisecting glcnac linked to a core beta-mannose..
10/10/13
20130266576
Therapeutic factor viii antibodies
The present invention relates to therapeutic fviii antibodies. In particular, the present invention relates to fviii antibodies having the ability to prolong the circulatory half life of fviii.
07/25/13
20130190242
Polymer-von willebrand factor-conjugates
The present invention relates to a proteinaceous construct (also designated as polymer-vwf-conjugate) comprising plasmatic and/or recombinant von willebrand factor (vwf), said vwf being bound to at least one physiologically acceptable polymer molecule, as well as to a complex between said proteinaceous construct and at least one factor viii (fviii) protein. The physiologically acceptable polymer molecule can be, for instance, polyethylene glycol (peg) or polysialic acid (psa).
07/25/13
20130189239
Conjugated factor viii molecules
The present invention relates to b-domain truncated factor viii molecules with a modified circulatory half life, said molecule being covalently conjugated with a hydrophilic polymer. The invention furthermore relates to methods for obtaining such molecules as well as use of such molecules..
07/18/13
20130184216
Novel albumin-free factor viii formulations
A factor viii composition formulated without albumin, comprising the following formulation excipients in addition to factor viii: 4% to 10% of a bulking agent selected from the group consisting of mannitol, glycine and alanine; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mm to 5 mm calcium salt; 100 mm to 300 mm nacl; and a buffering agent for maintaining a ph of approximately between 6 and 8. Alternatively, the formulation can comprise 2% to 6% hydroxyethyl starch; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mm to 5 mm calcium salt; 100 mm to 300 mm nacl; and a buffering agent for maintaining a ph of approximately between 6 and 8.
07/18/13
20130183280
Stabilized factor viii variants
The present invention relates to modified coagulation factors. In particular, the present invention relates to stabilized factor viii molecules conjugated with a half life extending moiety as well as use of such molecules..
06/13/13
20130150302
Conjugated blood coagulation factor viii
The present invention provides a biocompatible polymer conjugated to fviii via one or more cysteine residues, suitably via a linker across a reduced disulphide bond in fviii, and pharmaceutical compositions comprising such conjugated forms of fviii.. .
06/06/13
20130143818
Factor viii glycoforms
The invention concerns glycosylated proteins having human factor viii activity. In a preferred embodiment, the protein is glycosylated with oligosaccharides that include an alpha-(2,6)-linked sialic acid and a bisecting glcnac linked to a core beta-mannose..
05/30/13
20130137638
Conjugated factor viii molecules
The present invention relates to b-domain truncated factor viii molecules with a modified circulatory half life, said molecule being covalently conjugated with a hydrophilic polymer. The invention furthermore relates to methods for obtaining such molecules as well as use of such molecules..
05/30/13
20130136750
Antibodies which bind factor viii
The invention, in general, features a method of treatment and/or prevention of a thrombotic pathological condition, in a mammal, which includes administering to the mammal in need of such treatment a therapeutically effective amount of a composition including an antibody directed against the c1 domain of factor viii, which is a partially inhibitory antibody of factor viii.. .
05/16/13
20130123181
Factor viii t cell epitope variants having reduced immunogenicity
Provided herein are methods and compositions for preventing or reducing an initial immune response to factor viii in patients suffering from hemophilia a, and for reducing the intensity of the immune response in patients having pre-formed inhibitor antibodies against factor viii.. .
05/09/13
20130116182
Factor viii b cell epitope variants having reduced immunogenicity
Provided herein are methods and compositions for preventing or reducing an initial immune response to factor viii in patients suffering from hemophilia a, and for reducing the intensity of the immune response in patients having pre-formed inhibitor antibodies against factor viii.. .
05/09/13
20130115621
Highly sensitive immunoassays and antibodies for detection of blood factor viii
Disclosed are antibodies that selectively bind to blood coagulation factor fviii, and highly sensitive immunological assays comprising these antibodies. Preferred assays can detect fviii at about 3500-fold below the normal physiological levels, and have a wide array of applications including accurate monitoring of fviii concentration in pharmaceutical products for treatment of blood coagulation disorders, and determination of fviii levels in plasma of human patients, including those with blood coagulation disorders such as hemophilia..
05/02/13
20130108629
Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
The present invention provides methods of administering factor viii; methods of administering chimeric and hybrid polypeptides comprising factor viii; chimeric and hybrid polypeptides comprising factor viii; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.. .
04/04/13
20130085110
Recombinant factor viii having increased stability
The present invention relates to a recombinant factor viii that includes one or more mutations that result in enhanced stability of both factor viii and factor viiia. Methods of making and using the recombinant factor viii, and pharmaceutical compositions containing the same are also disclosed.
03/21/13
20130072434
Inactivation resistant factor viii
The present invention provides novel purified and isolated nucleic acid sequences encoding procoagulant-active fviii proteins. The nucleic acid sequences may encode amino acid sequences corresponding to known human fviii sequences, wherein residue phe309 is mutated.
03/21/13
20130071361
Methods of treatment of hemophilia
The present invention provides methods of treating hemophilia in a subject, the methods comprising transplanting a therapeutically effective amount of bone marrow, cord blood, cord blood or bone marrow fraction expressing factor viii, mononuclear cells, or mesenchymal stromal cells from a donor to the subject with hemophilia. The present invention also provides compositions for treating hemophilia..
02/28/13
20130052672
Kit for measuring the thrombin generation in a sample of a sample of a patient's blood or plasma
The invention provides a kit for measuring the thrombin generation in a sample of a patient's blood or plasma, or in a sample of clotting factors. The kit contains lyophilized tissue factor/phospholipid-complex and a lyophilized mixture containing a thrombin-substrate and cacl2.
02/14/13
20130040889
Factor viii fusion protein
The present invention relates to modified coagulation factors. In particular, the present invention relates to conjugated factor viii molecules fused to a polypeptide such as e.g.
02/14/13
20130040888
Factor viii molecules with reduced vwf binding
The present invention relates to a recombinant factor viii molecule, wherein said molecule has reduced vwf binding capacity, and wherein said molecule is covalently conjugated with at least one side group.. .
01/24/13
20130024960
Optimised coding sequence and promoter
An optimized coding sequence of human blood clotting factor eight (viii) and a promoter may be used in vectors, such as raav, for introduction of factor viii, and/or other blood clotting factors and transgenes. Exemplary of these factors and transgenes are alpha-1-antitrypsin, as well as those involved in the coagulation cascade, hepatocye biology, lysosomal storage, urea cycle disorders, and lipid storage diseases.


Popular terms: [SEARCH]

Factor Viii topics: Factor Viii, Nucleotide, Antibodies, Polynucleotide, Polypeptide, Sialic Acid, Circulatory, Recombinant, Ethylene Glycol, Coagulation, Hemophilia, Physiologic, Endogenous, Prophylaxis, Blood Coagulation

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patents related to Factor Viii for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Factor Viii with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         


FreshNews promo



1.268

3381

3 - 0 - 72